KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Assets (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Non-Current Assets for 16 consecutive years, with $13.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 14.19% to $13.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.3 million through Dec 2025, down 10.02% year-over-year, with the annual reading at $13.2 million for FY2025, 14.19% down from the prior year.
  • Non-Current Assets hit $13.2 million in Q4 2025 for Inovio Pharmaceuticals, down from $14.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $66.4 million in Q1 2021 to a low of $13.2 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $29.9 million across 5 years, with a median of $24.0 million in 2023.
  • Biggest five-year swings in Non-Current Assets: rose 4.81% in 2021 and later tumbled 56.11% in 2023.
  • Year by year, Non-Current Assets stood at $47.5 million in 2021, then fell by 29.91% to $33.3 million in 2022, then crashed by 46.42% to $17.8 million in 2023, then decreased by 13.85% to $15.4 million in 2024, then fell by 14.19% to $13.2 million in 2025.
  • Business Quant data shows Non-Current Assets for INO at $13.2 million in Q4 2025, $14.2 million in Q3 2025, and $15.5 million in Q2 2025.